ClinicalTrials.gg
RecruitingNCT06089031BELmicroUpdated Oct 18, 2023

Belgian Registry on Coronary Function Testing

An observational study in Coronary Microvascular Dysfunction and Coronary Artery Vasospasm, sponsored by University Hospital, Antwerp. Recruiting at 13 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.

Sponsored by University Hospital, Antwerp · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
650
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this prospective, multicenter registy is to describe the 'real-world' use of coronary function tests, which may consist of bolus thermodilution measurements of coronary microvascular function and/or invasive vasoreactivity tests with acetylcholine, in the current Belgian routine practice. The main questions it aims to answer are:

  • how frequent are coronary function tests performed
  • what is the indication for coronary function tests
  • what is the frequency of coronary microvascular dysfunction
  • what is the frequency of coronary artery vasospasm

From each participant, data will be collected from their medical files concerning cardiovascular risk factors, relevant past medical history, non-invasive tests, procedural data, and follow-up data from routine in-patient visits. Their are no specific study visits. Optionally, patients will be asked to fill in questionnaires about anginal symptoms and quality of life.

02

Conditions studied

  • Coronary Microvascular Dysfunction
  • Coronary Artery Vasospasm

Browse trials for

03

In context

Coronary Vasospasm

27 studies on the registry are indexed under Coronary Vasospasm; 7 are open to participants now.

This study's planned enrollment of 650 is above the median of 380 across 12 observational studies indexed under Coronary Vasospasm.

Browse Coronary Vasospasm studies →

Lead sponsor

University Hospital, Antwerp is the lead sponsor of 243 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Current registry includes each patient in which coronary function tests are performed. The indication for coronary function tests is left to the descretion of the operator. The study population will be broader than the classic use of coronary function tests for angina and non-obstructive coronary arteries (ANOCA).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient scheduled for coronary function test, comprising of intracoronary bolus thermodilution measurements of microvascular function, and/or intracoronary vasoreactivity tests with acetylcholine.
  • Subject understands the study requirements and provides written .

Exclusion criteria

Exclusion Criteria:

  • Subject is participating in another clinical trial that may cause non-compliance with the protocol or confound data interpretation.
  • Subject intends to participate in another investigational clinical trial that may cause non-compliance with the protocol or confound data interpretation.
  • Documented or suspected pregnancy.
  • Inability to provide written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
650 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • BELmicro

    No intervention foreseen.

    Diagnostic Test: Coronary Function Test

Interventions

  • Diagnostic testCoronary Function Test

    Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.

06

What researchers measure

Primary outcomes

  1. Frequency of coronary microvascular dysfunction and/or coronary artery vasospasm

    To measure the frequency of coronary microvascular dysfunciton coronary artery and vasomotor disorders among patients undergoing coronary function tests.

    Time frame: 5 years

Secondary outcomes

  1. Describe predictors for coronary microvascular dysfunction and/or coronary artery vasospasm

    To find predictors for coronary microvascular dysfunction and/or coronary artery vasospasm by means of multivariate regression analysis.

    Time frame: 5 years

  2. Describe 1- year and 3-year MACE among the different endotypes of coronary microvascular dysfunction with/whithout coronary artery spasm.

    To describe the difference in 1-year and 3-year MACE between the different endotypes of coronary microvascular dysfunction obtained.

    Time frame: 5 years

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Dec 2025, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 18, 2023
StartActual
Oct 18, 2021
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Oct 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06089031
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Oct 18, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion